SLU-PP-322
pharmaceuticalevidence: emerging · v1Description
SLU-PP-322 is an estrogen-related receptor (ERR) agonist research compound studied in mitochondrial-metabolism research models. Lyophilized powder. Reconstitute with bacteriostatic water for in-vitro research. Store at -20°C. Certificate of Analysis attached to this listing.
Mechanism summary
SLU-PP-332 is a synthetic small-molecule pan-agonist of the estrogen-related receptors (ERRα, ERRβ, and ERRγ) that activates transcription factors controlling mitochondrial biogenesis, fatty acid oxidation, and aerobic gene programs, mimicking the effects of endurance exercise. [Source: Peptide Dosing Protocols]
How it works
SLU-PP-332 is a synthetic small-molecule pan-agonist of the estrogen-related receptors (ERRα, ERRβ, and ERRγ). ERRs are nuclear receptors that sit upstream of mitochondrial biogenesis, fatty acid oxidation, and the aerobic gene program activated by endurance exercise. In plain English, SLU-PP-332 flips many of the same intracellular switches that training flips, which is why it is often described as an exercise mimetic.
Short version: SLU-PP-332 binds to ERRα, and to a lesser extent ERRβ and ERRγ. These are transcription factors in the cell nucleus that control how many mitochondria a cell builds, how efficiently those mitochondria burn fat, and how much oxidative capacity the cell has. When you run, muscle cells upregulate these same receptors. SLU-PP-332 does it pharmacologically. Think of ERRα as the master volume knob for a cell's aerobic machinery — SLU-PP-332 turns that knob up.
ERRα agonism is the primary driver of SLU-PP-332's effects. In preclinical studies, it has been shown to increase treadmill endurance, raise oxidative muscle fibers, and improve metabolic parameters in various mouse models. For instance, in the study by Billon 2023, mice dosed with 25 mg/kg IP for 15 days showed increased treadmill endurance, while 50 mg/kg twice daily for 28 days raised oxidative muscle fibers and OXPHOS proteins. Additionally, the study by Xu 2024 demonstrated improved cardiac function in a heart-failure model, indicating ERRγ's role in cardiomyocytes. Overall, SLU-PP-332's mechanism involves enhancing mitochondrial function and metabolic efficiency, mimicking the physiological adaptations of endurance training. [Source: Peptide Dosing Protocols]
In plain language
SLU-PP-332 works by activating certain receptors in the body that help improve energy production and fat burning, mimicking the effects of exercise.
Reference details
Route(s)
—
Tags
—
Active
yes
Product details · SLU5
Price
$59.99
Stock
out of stock
Teton Labs product catalog · research-use compound data.
💉 Dosing — 1 reference (verbatim from source · not a recommendation)
Dose
Standard: 50 mg (1 tablet) · Low: ≤1.5 mg · High: 100 mg (2 tablets)
Route
oral
Frequency
once daily
Cycle
6 weeks IP dosing (Burris-lab standard) Improved ejection fraction; reduced fibrosis; increased survival in the TAC model.
Reconstitution
5 mg vial reconstituted with 2 mL BAC water (2,500 mcg/mL) and a daily 500 mcg subcutaneous draw — a common community pattern, not a clinically validated dose.
Source: Peptide Dosing Protocols (peptidedosingprotocols.com) (publication)Source-backedProvider-reviewed
Safety, contraindications & monitoring
Contraindications — who should avoid
- Not FDA-approved.
- No information on who should avoid it stated.
Safety & side effects
- No human safety margin established.
- No human clinical trial program as of June 2026.
Monitoring & bloodwork
- No specific monitoring or bloodwork items stated.
Clinical evidence
- A single 25 mg/kg intraperitoneal dose in mice was enough to induce an acute aerobic exercise transcriptional signature in muscle within hours. · Billon 2023
- In a pressure-overload heart-failure mouse model, six weeks of SLU-PP-332 improved ejection fraction, reduced fibrosis, and increased survival. · Xu 2024
- In diet-induced obese mice, 50 mg/kg twice daily for 28 days increased whole-body energy expenditure and fatty acid oxidation. · Billon 2024
- 50 mg/kg twice daily for 28 days increased succinate dehydrogenase-positive oxidative muscle fibers and raised OXPHOS complex protein levels. · Billon 2023
Source-backedProvider-reviewedApproved findings drawn from your sources — decision support, not medical advice.
Provider-only reference. This page does not constitute medical advice, a recommendation, or dosing guidance.